These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 31501963)

  • 1. Computational modeling of therapy on pancreatic cancer in its early stages.
    Chen J; Weihs D; Vermolen FJ
    Biomech Model Mechanobiol; 2020 Apr; 19(2):427-444. PubMed ID: 31501963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer.
    Jacobetz MA; Chan DS; Neesse A; Bapiro TE; Cook N; Frese KK; Feig C; Nakagawa T; Caldwell ME; Zecchini HI; Lolkema MP; Jiang P; Kultti A; Thompson CB; Maneval DC; Jodrell DI; Frost GI; Shepard HM; Skepper JN; Tuveson DA
    Gut; 2013 Jan; 62(1):112-20. PubMed ID: 22466618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.
    Provenzano PP; Cuevas C; Chang AE; Goel VK; Von Hoff DD; Hingorani SR
    Cancer Cell; 2012 Mar; 21(3):418-29. PubMed ID: 22439937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer.
    Hingorani SR; Harris WP; Beck JT; Berdov BA; Wagner SA; Pshevlotsky EM; Tjulandin SA; Gladkov OA; Holcombe RF; Korn R; Raghunand N; Dychter S; Jiang P; Shepard HM; Devoe CE
    Clin Cancer Res; 2016 Jun; 22(12):2848-54. PubMed ID: 26813359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
    Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma.
    Hingorani SR; Zheng L; Bullock AJ; Seery TE; Harris WP; Sigal DS; Braiteh F; Ritch PS; Zalupski MM; Bahary N; Oberstein PE; Wang-Gillam A; Wu W; Chondros D; Jiang P; Khelifa S; Pu J; Aldrich C; Hendifar AE
    J Clin Oncol; 2018 Feb; 36(4):359-366. PubMed ID: 29232172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer.
    Doherty GJ; Tempero M; Corrie PG
    Future Oncol; 2018 Jan; 14(1):13-22. PubMed ID: 29235360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive modeling of in vivo response to gemcitabine in pancreatic cancer.
    Lee JJ; Huang J; England CG; McNally LR; Frieboes HB
    PLoS Comput Biol; 2013; 9(9):e1003231. PubMed ID: 24068909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma.
    Van Cutsem E; Tempero MA; Sigal D; Oh DY; Fazio N; Macarulla T; Hitre E; Hammel P; Hendifar AE; Bates SE; Li CP; Hingorani SR; de la Fouchardiere C; Kasi A; Heinemann V; Maraveyas A; Bahary N; Layos L; Sahai V; Zheng L; Lacy J; Park JO; Portales F; Oberstein P; Wu W; Chondros D; Bullock AJ;
    J Clin Oncol; 2020 Sep; 38(27):3185-3194. PubMed ID: 32706635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silencing PCBP2 normalizes desmoplastic stroma and improves the antitumor activity of chemotherapy in pancreatic cancer.
    Li Y; Zhao Z; Lin CY; Liu Y; Staveley-OCarroll KF; Li G; Cheng K
    Theranostics; 2021; 11(5):2182-2200. PubMed ID: 33500719
    [No Abstract]   [Full Text] [Related]  

  • 11. Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice.
    Peran I; Dakshanamurthy S; McCoy MD; Mavropoulos A; Allo B; Sebastian A; Hum NR; Sprague SC; Martin KA; Pishvaian MJ; Vietsch EE; Wellstein A; Atkins MB; Weiner LM; Quong AA; Loots GG; Yoo SS; Assefnia S; Byers SW
    Gastroenterology; 2021 Mar; 160(4):1359-1372.e13. PubMed ID: 33307028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic Contrast-enhanced MRI Detects Responses to Stroma-directed Therapy in Mouse Models of Pancreatic Ductal Adenocarcinoma.
    Cao J; Pickup S; Clendenin C; Blouw B; Choi H; Kang D; Rosen M; O'Dwyer PJ; Zhou R
    Clin Cancer Res; 2019 Apr; 25(7):2314-2322. PubMed ID: 30587546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
    Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PEGPH20 for metastatic pancreatic ductal adenocarcinoma.
    Gourd E
    Lancet Oncol; 2018 Feb; 19(2):e81. PubMed ID: 29276021
    [No Abstract]   [Full Text] [Related]  

  • 15. Identification of a novel subpopulation of tumor-initiating cells from gemcitabine-resistant pancreatic ductal adenocarcinoma patients.
    Shimizu K; Chiba S; Hori Y
    PLoS One; 2013; 8(11):e81283. PubMed ID: 24278411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.
    Liu Y; Li F; Gao F; Xing L; Qin P; Liang X; Zhang J; Qiao X; Lin L; Zhao Q; Du L
    Tumour Biol; 2016 Nov; 37(11):15283-15291. PubMed ID: 27696296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting Gemcitabine Delivery by
    Russell J; Grkovski M; O'Donoghue IJ; Kalidindi TM; Pillarsetty N; Burnazi EM; Kulick A; Bahr A; Chang Q; LeKaye HC; de Stanchina E; Yu KH; Humm JL
    J Nucl Med; 2021 Feb; 62(2):195-200. PubMed ID: 32646874
    [No Abstract]   [Full Text] [Related]  

  • 18. Tissue Transglutaminase Activates Cancer-Associated Fibroblasts and Contributes to Gemcitabine Resistance in Pancreatic Cancer.
    Lee J; Yakubov B; Ivan C; Jones DR; Caperell-Grant A; Fishel M; Cardenas H; Matei D
    Neoplasia; 2016 Nov; 18(11):689-698. PubMed ID: 27792935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secretion of fibronectin by human pancreatic stellate cells promotes chemoresistance to gemcitabine in pancreatic cancer cells.
    Amrutkar M; Aasrum M; Verbeke CS; Gladhaug IP
    BMC Cancer; 2019 Jun; 19(1):596. PubMed ID: 31208372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-Bv8 antibody and metronomic gemcitabine improve pancreatic adenocarcinoma treatment outcome following weekly gemcitabine therapy.
    Hasnis E; Alishekevitz D; Gingis-Veltski S; Bril R; Fremder E; Voloshin T; Raviv Z; Karban A; Shaked Y
    Neoplasia; 2014 Jun; 16(6):501-10. PubMed ID: 24957319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.